Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens - Rickli, Anna; Moning, Olivier D.; Hoener, Marius C.; Liechti, Matthias E. (European neuropsychopharmacology, 2016)
Keywords: Animals; Biogenic Monoamines - metabolism; Cell Survival - drug effects; DMT; Hallucinogens; Hallucinogens - chemistry; Hallucinogens - metabolism; Hallucinogens - pharmacology; HEK293 Cells; Humans; Internal Medicine; Kinetics; Ligands; LSD; Membrane Transport Modulators - chemistry; Membrane Transport Modulators - metabolism; Membrane Transport Modulators - pharmacology; Mescaline; Mice; Molecular Structure; NIH 3T3 Cells; Psilocybin; Psychiatry; Psychotropic Drugs - chemistry; Psychotropic Drugs - metabolism; Psychotropic Drugs - pharmacology; Radioligand Assay; Receptor, Serotonin, 5-HT2A - chemistry; Receptor, Serotonin, 5-HT2A - genetics; Receptor, Serotonin, 5-HT2A - metabolism; Receptor, Serotonin, 5-HT2B - chemistry; Receptor, Serotonin, 5-HT2B - genetics; Receptor, Serotonin, 5-HT2B - metabolism; Receptor, Serotonin, 5-HT2C - chemistry; Receptor, Serotonin, 5-HT2C - genetics; Receptor, Serotonin, 5-HT2C - metabolism; Recombinant Proteins - chemistry; Recombinant Proteins - metabolism; Serotonin 5-HT2 Receptor Agonists - chemistry; Serotonin 5-HT2 Receptor Agonists - metabolism; Serotonin 5-HT2 Receptor Agonists - pharmacology; Structure-Activity Relationship; Tryptamines; Tryptamines - chemistry; Tryptamines - metabolism; Tryptamines - pharmacology; Vesicular Monoamine Transport Proteins - antagonists & inhibitors; Vesicular Monoamine Transport Proteins - genetics; Vesicular Monoamine Transport Proteins - metabolism; DMT; Psilocybin; Tryptamines; LSD; Hallucinogens; Mescaline